Whether the “little pink pill” is a boon or a boondoggle depends on who you ask Flibanserin, soon to be marketed as Addyi, has been in clinical trials to treat low desire since the mid-2000s.

The Food and Drug Administration is due to announce whether it will approve Flibanserin, a drug shown to boost women's libido, which has been rejected twice before. Mark Kelly reports. Photo: AP ...